<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705171</url>
  </required_header>
  <id_info>
    <org_study_id>GGP1345012</org_study_id>
    <secondary_id>GLUT5</secondary_id>
    <nct_id>NCT01705171</nct_id>
  </id_info>
  <brief_title>Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?</brief_title>
  <official_title>Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brain-Gut Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brain-Gut Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we will investigate the expression of the fructose transport protein GLUT5 in&#xD;
      the small intestine in patients with functional GI disoders and fructose intolerance compared&#xD;
      to matched healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intolerances to food are a major complaint of patients with functional gastrointestinal&#xD;
      disorders (FGID) and even commoner in patients with inflammatory bowel disorders (IBD)&#xD;
      (Barrett JS et al. Aliment Pharmacol Therap 2009;30:165-174). The most common forms of food&#xD;
      intolerance are FODMAP (fermentable oligo-, di- and monosaccharide and polyol) -related, of&#xD;
      which fructose and lactose are the best known. The prevalence of lactose and fructose&#xD;
      intolerance in IBS patients is between 50 and 70% (Wilder-Smith CH et al. Gastroenterology&#xD;
      2009;136 (Suppl. 1): A324). Recent high quality studies have shown that the reduction of&#xD;
      ingested FODMAP can lead to significant and long-term symptom improvement in patients shown&#xD;
      to be intolerant by breath-testing. While the pathophysiology behind lactose intolerance is&#xD;
      the reduction in small intestinal lactase availability, the mechanism in fructose intolerance&#xD;
      and its relationship to malabsorption are unknown. One possible and so far uninvestigated&#xD;
      mechanism is a reduction in the expression or activity of the specific fructose transporter,&#xD;
      GLUT5, which is mainly responsible for luminal absorption of fructose. GLUT5 is mainly found&#xD;
      in the small intestine, as well as various extra-intestinal organs. The clinical relevance of&#xD;
      GLUT5 expression for food intolerances in humans has not been reported, but in a mouse model&#xD;
      deletion of GLUT5 led to decreased absorption of dietary fructose and typical signs of&#xD;
      malabsorption (Barone S et al. J Biol Chem 2009;284:5056-5066). The control of GLUT5 is&#xD;
      dynamic and considerable upregulation together with increased absorption of fructose is&#xD;
      evident in diabetes mellitus, while expression is decreased by inflammation and&#xD;
      lipopolysaccharide endotoxin, an integral component of the outer membrane of all&#xD;
      gram-negative bacteria, through the action of pro-inflammatory cytokines, such as TFN-a.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mRNA and protein expression of Glut5</measure>
    <time_frame>on day of endoscopy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRNA and protein expression of Glut2</measure>
    <time_frame>on day of endoscopy</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Fructose Intolerance</condition>
  <arm_group>
    <arm_group_label>IBS patients with fructose intolerance</arm_group_label>
    <description>analysis of biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: no IBS or fructose intolerance</arm_group_label>
    <description>analysis of biopsies</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred to our practice for evaluation of symptoms consistent with FGID&#xD;
        undergoing upper GI endoscopy with biopsy and fructose breath testing as part of their&#xD;
        usual clinical evaluation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients referred to our practice for evaluation of symptoms consistent with FGID&#xD;
             undergoing upper GI endoscopy with biopsy and fructose breath testing as part of their&#xD;
             usual clinical evaluation. Male or female patients aged between 18 and 60 years with&#xD;
             FGID (Irritable Bowel Syndrome (IBS), Functional Dyspepsia (FD) or Functional Bloating&#xD;
             (FB), as defined by Rome III criteria.&#xD;
&#xD;
          -  Successive patients without fructose intolerance undergoing upper GI endoscopy for&#xD;
             other reasons without inflammatory disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory GI disease, coeliac's disease, other relevant systemic disorders as&#xD;
             judged by investigator, concomitant antiinflammtory treatments, absent informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Wilder-Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain-Gut Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastoenterology Group Practice</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 9, 2012</study_first_submitted>
  <study_first_submitted_qc>October 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brain-Gut Research Group</investigator_affiliation>
    <investigator_full_name>C. Wilder-Smith</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>fructose intolerance</keyword>
  <keyword>GLUT 5</keyword>
  <keyword>GLUT 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Fructose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

